CClinicalTrials.gg
CompletedNCT03076671MTMDUpdated May 14, 2021

More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease

An interventional study of Palliative Care in Parkinson Disease, Parkinsonism and Lewy Body Disease, sponsored by University of Colorado, Denver. Completed at 2 sites in United States. Open to participants aged 18 Years to 105 Years. Per ClinicalTrials.gov, last updated 2021-05-14.

Sponsored by University of Colorado, Denver · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
783
Allocation
Randomized
Ages
18 Years to 105 Years
Sex
All
01

Study summary

This is a two-center (University of Colorado, University of California San Francisco) community-based comparative effectiveness study of outpatient palliative care for Parkinson's disease (PD) and related disorders (progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), multiple systems atrophy (MSA), Lewy Body Dementia (LBD). In September 2018, the study was amended to also include Alzheimer's disease (AD) and related disorders (Frontotemporal Dementia (FTD), Primary Progressive Aphasia (PPA), Vascular Dementia). It will utilize a randomized stepped-wedge design to compare patient and caregiver outcomes between usual care in the community versus usual care augmented by palliative training and telemedicine support to provide other resources (e.g. social work).

Read the detailed description

Parkinson's disease (PD) is the second most common neurodegenerative illness affecting approximately 1.5 million Americans and is the 14th leading cause of death in the United States. PD is traditionally described as a movement disorder with characteristic motor symptoms (e.g. tremor). However, more recent research demonstrates the impact of nonmotor symptoms such as pain, depression, and dementia on mortality, quality of life (QOL), nursing home placement and caregiver distress. Regarding models of care for PD, evidence suggests that care including a neurologist results in lower mortality and nursing home placement than care solely from a primary care physician. Unfortunately, there is also significant evidence that many of the needs most important to PD patients and their caregivers (e.g. depression, planning for the future) are poorly addressed under current models of care. Palliative care is an approach to caring for individuals with life-threatening illnesses that focuses on addressing potential causes of suffering including physical and psychiatric symptoms, psychosocial issues and spiritual needs. While developed for cancer patients, palliative care approaches have been successfully applied in other chronic progressive illnesses including heart failure and pulmonary disease. To date there have been minimal attempts to apply these principles to PD although evidence suggests that PD patients' unmet needs under current models of care may be amenable to palliative care. A small but growing cadre of centers offer outpatient palliative care for PD with early evidence of efficacy and a randomized trial of an academic-based outpatient palliative care is underway led by investigators on this proposal. While this work is critical to forwarding this field, further work is needed to provide a model that can be widely disseminated. The current proposal addresses this gap by assessing the effectiveness and feasibility of a novel community-based intervention that empowers community neurology practices to improve care for PD patients and caregivers through palliative care training, coaching and telemedicine resources. The investigators hypothesize that this intervention will improve patient QOL and caregiver burden and will prove feasible and acceptable to community providers. The investigators Specific Aims are to: 1) Determine the a) effectiveness and b) feasibility of a novel community-based outpatient palliative care intervention for PD.; 2) Describe the effects of a this intervention on patient and caregiver costs and service utilization; and 3) Identify opportunities to optimize community-based palliative care for this population by: a) describing patient and caregiver characteristics associated with intervention benefits; and b) through direct patient, caregiver and provider interviews. Innovations of the investigators approach include a novel model of providing disease-specific community-based palliative care not dependent on limited palliative specialist resources, a stepped-wedge trial design and use of telemedicine resources to provide multidisciplinary care. The research is significant because it will create a foundation for future community-based dissemination studies in PD and the broader field of palliative care.

In September 2018, supplemental support from NIH was granted in order to explore outcomes among an Alzheimer's dementia population. Alzheimer's disease (AD) is the most common neurodegenerative illness affecting 10% of adults over age 65. This incurable and relentlessly progressive disease affects approximately 1.5 million Americans and is the 6th leading cause of death in the United States. Care for community-dwelling patients with AD is typically focused on the assessment and pharmacologic management of cognitive and behavioral symptoms, although there is growing recognition of the need to expand care to address other issues, including advance care planning. There is significant evidence that many of the most important needs of the AD patients and their caregivers are poorly addressed under current models of care, including management of medical and psychiatric symptoms (e.g. pain and depression), caregiver support, advance care planning, and spiritual wellbeing. Importantly, while the top goal of care for the majority of patients is avoidance of institutionalization, our current models of care invest more resources in institutionalized patients rather than proactively supporting community-dwelling individuals which may prevent institutionalization and reduce overall healthcare costs. Our supplemental study will thus additionally target this population for a 12-month period.

02

Conditions studied

  • Parkinson Disease
  • Parkinsonism
  • Lewy Body Disease
  • Supranuclear Palsy, Progressive
  • Parkinsonism Vascular
  • Multiple System Atrophy
  • Corticobasal Degeneration
  • Alzheimer Disease
  • Frontotemporal Dementia
  • Primary Progressive Aphasia
  • Vascular Dementia

Keywords

  • Palliative Care
  • Supportive Care
  • Movement Disorders
  • Brain Disease
  • Neurodegeneration
  • Parkinson's Disease
  • Alzheimer's Disease
03

In context

Parkinson Disease

4,487 studies on the registry are indexed under Parkinson Disease; 1,082 are open to participants now.

This study's enrollment of 783 is above the median of 40 across 3,294 interventional studies indexed under Parkinson Disease.

Browse Parkinson Disease studies →

Lead sponsor

University of Colorado, Denver is the lead sponsor of 1,499 studies on the registry; 315 are open to participants now.

Of its 139 completed or terminated interventional studies of FDA-regulated products, 89 (64%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 105 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients must be fluent English Speakers,
  • Must be over age 18,
  • They must meet United Kingdom (UK) Brain Bank criteria for probable PD, or
  • They must meet standard criteria for

    • progressive supranuclear palsy (PSP),
    • corticobasal degeneration (CBD),
    • multiple systems atrophy (MSA),
    • vascular parkinsonism, or
    • Lewy Body Dementia (LBD)
    • Alzheimer's dementia (AD)
    • Primary progressive aphasia
    • Vascular dementia.
  • Patients must be at high risk for poor outcomes as defined by the Brief Needs Assessment Tool (BNAT) which screens for psychosocial issues, symptoms, and caregiver burden.
  • Caregivers will be identified by asking the patient: "Could (participant) tell us the one person who helps (participant) the most with (participant's) PD outside of clinic?"
  • Caregivers may be self-identified in cases of severe dementia in order to obtain data relevant to this vulnerable and underrepresented group.

Exclusion criteria

Exclusion Criteria:

  • Unable or unwilling to commit to study procedures;
  • Presence of additional chronic medical illnesses which may require palliative services (e.g. metastatic cancer); or
  • Already receiving palliative care or hospice services.
  • Not expecting to continue care with enrolled physician for at least 6 months.

The investigators have purposefully kept our inclusion/exclusion criteria broad to allow for greater generalizability of results and to ensure inclusion of potentially underrepresented and understudied subgroups.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
783 participants (actual)

Study arms

  • No intervention
    Standard of Care

    Patients to get usual care from their established neurology care team that is enrolled in the study.

  • Experimental
    Standard of Care plus Palliative Care

    Patients to get usual care, augmented by palliative care, provided by their established neurology care team that is affiliated with the study, with additional support provided by the University of Colorado Denver Neurology Palliative Care team.

    Behavioral: Palliative Care

  • Experimental
    Clinicians

    Clinicians enrolled in the study will receive an 8-hour supportive and palliative care training, followed by monthly coaching and the availability of telemedicine visits for enrolled patients with the university neuro-palliative care team. The unit of randomization is the time when they receive training. Four to five clinical practices will receive training every 6 months during years 2 and 3, at which time all of their enrolled patients will be switched from usual care to the intervention arm.

    Behavioral: Palliative Care

Interventions

  • BehavioralPalliative Care

    Palliative care training for community neurologists and use of telemedicine for team-based support of patients

    Also known as: Supportive Care

06

What researchers measure

Primary outcomes

  1. Quality of Life Alzheimer's Disease (QOL-AD)

    Measures of Quality of Life

    Time frame: Up to 48 months

  2. Zarit Burden of Care Instrument (ZBI)

    Measures of Care Partner Distress

    Time frame: Up to 48 months

Secondary outcomes

  1. McGill Quality of Life Questionnaire (MQOL)

    Measures of Quality of Life

    Time frame: Up to 48 months

  2. Hospital Anxiety and Depression Scale (HADS)

    Measures of mood

    Time frame: Up to 48 months

  3. Edmonton Symptom Assessment Scale (ESAS_PD)

    Measures of symptom burden

    Time frame: Up to 48 months

  4. Functional Assessment of Chronic Illness Therapy-Spiritual Wellbeing (FACIT-SP 12 Item)

    Measures of spiritual wellbeing

    Time frame: Up to 48 months

  5. Prolonged Grief Questionnaire (PG-12)

    Measures of grief (sense of loss)

    Time frame: Up to 48 months

  6. Semi-structured Qualitative Interview

    Measures of participant views on the study including their outcomes and the implementation of this model of community-based palliative care.

    Time frame: At 12 months

  7. Montreal Cognitive Assessment (MOCA)

    Measures of cognitive function

    Time frame: At baseline

  8. Healthcare Utilization Form

    Measures of type and frequency of healthcare utilized

    Time frame: Up to 48 months

  9. Palliative Performance Scale

    Measures of Disease Severity

    Time frame: Up to 48 months

  10. Clinical Global Impression of Change

    Measures of change in disease burden

    Time frame: Up to 48 months

  11. Treatment Documentation Form

    Measures of treatments used for disease management

    Time frame: Up to 48 months

  12. Modified Caregiver Strain Index

    Measures of care partner distress

    Time frame: Up to 48 months

  13. Needs at End of Life Screening Tool

    Detects and measures needs for end of life

    Time frame: Up to 12 months

  14. Neuropsychiatric Inventory

    Measures dementia-related symptoms

    Time frame: Up to 6 months

07

Study locations

2 sites
  • University of California, San Francisco
    San Francisco, California 94143, United States
  • University of Colorado Denver
    Aurora, Colorado 80045, United States
08

References and documents

Publications

  • Ayele R, Macchi ZA, Dini M, Bock M, Katz M, Pantilat SZ, Jones J, Kluger BM. Experience of Community Neurologists Providing Care for Patients With Neurodegenerative Illness During the COVID-19 Pandemic. Neurology. 2021 Sep 7;97(10):e988-e995. doi: 10.1212/WNL.0000000000012363. Epub 2021 Jun 14. PubMed 34489348 ↗
  • Macchi ZA, Ayele R, Dini M, Lamira J, Katz M, Pantilat SZ, Jones J, Kluger BM. Lessons from the COVID-19 pandemic for improving outpatient neuropalliative care: A qualitative study of patient and caregiver perspectives. Palliat Med. 2021 Jul;35(7):1258-1266. doi: 10.1177/02692163211017383. Epub 2021 May 18. PubMed 34006157 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03076671
Lead sponsor
University of Colorado, Denver
Collaborators
National Institute of Nursing Research (NINR), University of California, San Francisco
Responsible party
Sponsor
First posted
Mar 10, 2017
Start date
Mar 1, 2017
Primary completion
Dec 31, 2020
Completion
Dec 31, 2020
Last update
May 14, 2021

Study contacts

Benzi M Kluger, MD, MS
principal investigator · University of Colorado, Denver

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion